Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 31, 2025 • 4:11 PM ET

Date/Time Source News Release
03/18/2025 04:05 PM EDT PR Newswire INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
03/13/2025 06:15 PM EDT PR Newswire INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
03/12/2025 12:55 PM EDT PR Newswire INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
02/12/2025 08:00 AM EST PR Newswire Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
02/10/2025 08:05 AM EST PR Newswire Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
01/29/2025 04:14 PM EST PR Newswire INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
01/09/2025 08:04 AM EST PR Newswire INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
12/13/2024 07:00 AM EST PR Newswire INOVIO Announces Pricing of $30 Million Public Offering
12/12/2024 04:01 PM EST PR Newswire INOVIO Announces Proposed Public Offering
12/03/2024 08:00 AM EST PR Newswire New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Page

Additional News

As of March 31, 2025 • 4:11 PM ET

Date/Time Source News Release
03/19/2025 08:26 AM EDT SeekingAlpha Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues
03/18/2025 10:15 PM EDT Motley Fool Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript
03/18/2025 08:48 PM EDT SeekingAlpha Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
03/18/2025 04:27 PM EDT SeekingAlpha Earnings Snapshot: Inovio Pharmaceuticals tops Q4 estimates, records R&D expenses for $12.9M
03/18/2025 04:07 PM EDT SeekingAlpha Inovio Pharmaceuticals GAAP EPS of -$0.65 beats by $0.19, revenue of $0.12M
03/18/2025 10:00 AM EDT SeekingAlpha Here are the major earnings after the close today
03/18/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, March 18th, 2025
03/18/2025 05:31 AM EDT US Earnings Reports Expected earnings - Inovio Pharmaceuticals Inc.
03/17/2025 05:35 PM EDT SeekingAlpha Inovio Pharmaceuticals Q4 2024 Earnings Preview
03/16/2025 08:00 AM EDT SeekingAlpha Earnings week ahead: FDX, GIS, NIO, XPEV, MU, NKE, CCL, ACN and more
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.